ArticleFrontiers in oncology2025
The impact of radiotherapy on disease control in vulvar extramammary Paget's disease: a retrospective study from a single institution.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinicopathological Analysis of 40 Cases of Extramammary Paget Disease: A Retrospective Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Secondary Perianal Paget's Disease Originating From Adenocarcinoma of the Anorectal Junction: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Vulvar extramammary Paget's disease (EMPD) is a rare intraepithelial carcinoma that affects apocrine gland-bearing skin, predominantly in postmenopausal women. Due to its rarity, optimal treatment strategies, including the role of radiotherapy (RT), remain poorly established. This study aimed to evaluate the role of radiation therapy in vulvar EMPD, focusing on preserving functional and aesthetic vulvar tissue without compromising survival rates. Materials and methods: We conducted a retrospective cohort study of 32 patients diagnosed with vulvar EMPD at Seoul National University Hospital between 2000 and 2024. Clinicopathologic data, including demographics characteristics, clinical presentations, histopathological findings, treatment modalities, and outcomes, were collected. Patients were divided into two groups: those who received neoadjuvant or adjuvant RT ( Result: The median age at diagnosis was 63.8 years (range: 38.0-87.8), with 84.4% of patients being postmenopausal. Among the 32 patients, 30 (93.8%) underwent surgery, and nine (28.1%) received adjuvant RT. Recurrence rates were similar between the RT (66.7%) and non-RT (66.7%) groups. The median PFS was longer in the RT group (28.1 months) compared to the non-RT group (23.4 months), although this difference was not statistically significant ( Conclusion: In conclusion, although RT did not show a statistically significant survival benefit, both our data and previous studies strongly suggest that RT holds potential for disease control. It may be the primary treatment before and after surgery in patients with extensive vulvar EMPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.